Overview
Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table. It is used in various chemical, industrial and manufacturing applications such as wood preservation and metallurgy. The uses of chromium compounds depend on the valency of chromium, where trivalent Cr (III) compounds are used for dietary Cr supplementation and hexavalent Cr (VI) compounds are used as corrosion inhibitors in commercial settings and are known to be human carcinogens . Humans can be exposed to chromium via ingestion, inhalation, and dermal or ocular exposure . Trivalent chromium (Cr(III)) ion is considered to be an essential dietary trace element as it is involved in metabolism of blood glucose, regulation of insulin resistance and metabolism of lipids. Clinical trials and other studies suggest the evidence of chromium intake improving glucose tolerance in patients with Type I and II diabetes, however its clinical application in the standard management of type II diabetes mellitus is not established. Chromium deficiency has been associated with a diabetic-like state, impaired growth, decreased fertility and increased risk of cardiovascular diseases . According to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 μg and 25 μg, respectively . Chromium picolinate capsules may be used as nutritional adjuvant in patients with or at risk of type 2 diabetes mellitus (T2DM) to improve blood sugar metabolism and stabilize the levels of serum cholesterol. Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) .
Indication
Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms .
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/11/28 | Phase 4 | Active, not recruiting | |||
2024/05/08 | Phase 3 | Not yet recruiting | |||
2015/05/27 | Not Applicable | Completed | Sahlgrenska University Hospital, Sweden | ||
2012/10/17 | Not Applicable | Completed | Louisiana State University Health Sciences Center Shreveport | ||
2008/09/25 | Phase 2 | Terminated | State University of New York - Upstate Medical University | ||
2006/03/29 | Not Applicable | Completed | Nutrition 21, Inc. | ||
2006/02/09 | Not Applicable | Completed | Nutrition 21, Inc. |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Novian Pharmaceuticals | 83146-003 | ORAL | 35 ug in 1 1 | 10/6/2023 | |
Exeltis USA, Inc. | 0642-0207 | ORAL | 50 ug in 1 1 | 1/2/2023 | |
Acella Pharmaceuticals, LLC | 42192-374 | ORAL | 100 ug in 1 1 | 10/11/2023 | |
Perdido Key Health and Wellness Inc | 70104-128 | INTRAMUSCULAR | 1 mg in 1 mL | 11/23/2015 | |
Avion Pharmaceuticals, LLC | 75854-343 | ORAL | 100 ug in 1 1 | 10/11/2023 | |
Deseret Biologicals, Inc. | 43742-1312 | ORAL | 8 [hp_X] in 1 mL | 5/27/2025 | |
Dr. Donna Restivo DC | 62185-0062 | ORAL | 8 [hp_X] in 1 mL | 5/23/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
DANMOT HERBALIX CHELATION FORMULA tablet bulk | 52268 | Danmot Pty Ltd | Medicine | A | 4/18/1995 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
CHELA-CHROMIUM 200 | nu-life nutrition ltd. | 00668427 | Tablet - Oral | 200 MCG / TAB | 12/31/1986 |
CHILDRENS MULTI VIT AND CHELATED MINERALS | nu-life nutrition ltd. | 00645656 | Tablet - Oral | 1 MCG | 12/31/1987 |
MULTIVITAMINES & MINERAUX FORTES TAB | nobel pharm enr. | 00781061 | Tablet - Oral | 27 MCG / TAB | 12/31/1988 |
TWIN ULTRA LIQUID FRUIT PUNCH FLAVOR | twin laboratories inc. | 01984233 | Liquid - Oral | .4 MCG / ML | 12/31/1995 |
ONE A DAY ADVANCE ADULTS 50 PLUS TAB | miles canada inc. - consumer health care division | 02080702 | Tablet - Oral | 10 MCG / TAB | 12/31/1994 |
TWIN ULTRA LIQUID LEMON-LIME FLAVOR | twin laboratories inc. | 01984241 | Liquid - Oral | .4 MCG / ML | 12/31/1995 |
AVED GEST TAB | anabolic laboratories inc. | 00549568 | Tablet - Oral | 3.33 MCG | 12/31/1982 |
MULTI V+M CTR TAB | bioenergy inc. | 00539945 | Tablet (Extended-Release) - Oral | 25 MCG / TAB | 12/31/1979 |
TWIN ULTRA LIQUID GRAPE FLAVOR | twin laboratories inc. | 01984225 | Liquid - Oral | .4 MCG / ML | 12/31/1995 |
AVED M TAB | anabolic laboratories inc. | 00549959 | Tablet - Oral | 5 MCG | 12/31/1982 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.